Viatris prevails on Sanofi appeals of Lantus patent invalidations

30 December 2021

USA-based Viatris (Nasdaq: VTRS) announced that it is pleased with decisions issued that affirm the US Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's (Euronext: SAN) Lantus (insulin glargine) SoloSTAR device patents, US Patent Nos 9,603,044, 8,992,486, 9,526,844, 9,604,008, and 8,679,069, unpatentable.

These affirmances reinforce the company's continuing efforts to break down barriers to patient access for important medicines such as Semglee through its Global Healthcare Gateway. Viatris and its partner, India’s Biocon Biologics, a subsidiary of Biocon (BSE: 532523), launched their interchangeable Semglee products (insulin glargine-yfgn) last month. These are the first, and currently the only, interchangeable biosimilars to Lantus, providing more affordable options for the millions of Americans living with diabetes.

Substitution allowed at the pharmacy counter

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK